Gsk (GSK) Invested Capital (2014 - 2026)

Gsk's Invested Capital history runs 13 years deep, the most recent figure standing at -$7.3 billion for Q2 2026.

• In Q2 2026, Invested Capital changed 0.11% year-over-year to -$7.3 billion; the TTM figure through Jun 2026 stood at -$2.6 billion (down 110.63% YoY), while the FY2025 annual figure was $19.1 billion, down 59.43% from the prior year.
• Invested Capital for Q2 2026 stood at -$7.3 billion, down from -$7.1 billion in the prior quarter.
• The five-year high for Invested Capital was $47.2 billion in Q4 2024, with the low at -$7.8 billion in Q3 2024.
• The 5-year median for Invested Capital is -$7.0 billion (2023), against an average of $498.1 million.
• The sharpest annual moves came in 2023 and 2024: Invested Capital plunged 248.58% in 2023, then surged 152.64% in 2024.
• Gsk's Invested Capital stood at $20.2 billion in 2022, then declined by 7.46% to $18.7 billion in 2023, then soared by 152.64% to $47.2 billion in 2024, then sank by 59.24% to $19.2 billion in 2025, then slumped by 137.72% to -$7.3 billion in 2026.
• Business Quant data shows GSK's Invested Capital at -$7.3 billion in Q2 2026, -$7.1 billion in Q1 2026, and $19.2 billion in Q4 2025.